Comparative Pharmacology
Head-to-head clinical analysis: PIMECROLIMUS versus PROGRAF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIMECROLIMUS versus PROGRAF.
PIMECROLIMUS vs PROGRAF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Calcineurin inhibitor; binds to FKBP-12, inhibits calcineurin, preventing dephosphorylation and nuclear translocation of NF-AT, thereby inhibiting T-cell activation and cytokine gene transcription.
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
Initial oral dose: 0.1-0.15 mg/kg/day divided into 2 doses (every 12 hours). IV dose: 0.03-0.05 mg/kg/day as continuous infusion. Adjunct with corticosteroids.
None Documented
None Documented
Clinical Note
moderatePimecrolimus + Gatifloxacin
"Pimecrolimus may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePimecrolimus + Rosoxacin
"Pimecrolimus may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePimecrolimus + Levofloxacin
"Pimecrolimus may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePimecrolimus + Trovafloxacin
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Terminal elimination half-life is approximately 8.7 hours (range 4-41 hours) in healthy volunteers; in liver transplant patients, half-life is approximately 11.7 hours (range 3.9-56 hours); prolonged in patients with hepatic impairment.
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Primarily fecal (approximately 92%) with biliary excretion as the major route; renal excretion accounts for about 2.4% of the dose as unchanged drug and metabolites.
Category A/B
Category C
Calcineurin Inhibitor
Calcineurin Inhibitor
"Pimecrolimus may increase the neuroexcitatory activities of Trovafloxacin."